Oncotarget

In The News - Press Releases


Oncotarget: Progression in high-risk non-muscle invasive bladder cancer


FOR IMMEDIATE RELEASE
2021-04-29

Oncotarget published "A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer" which reported that a recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies.

This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.

This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC

Among these patients, 32 patients developed recurrent disease and 15 patients showed progression.

A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.

The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.

The De Ritis ratio might be a risk factor for progression in high-risk NMIBC

Dr. Takashi Kawahara from The Yokohama City University Medical Center said, "Bladder cancer is the eleventh most common malignant disease in the world, and non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases."

The serum aspartate aminotransaminase /alanine aminotransaminase ratio was first reported by De Ritis in 1957, since then this ratio has been called the De Ritis ratio.

A high De Ritis ratio was reported to be a poor prognostic marker in some solid malignancies.

In genitourinary cancer, a high De Ritis ratio was reported to be a poor prognostic marker in prostate, renal, and urothelial carcinoma.

In other solid malignancies including breast and lung cancer, a high De Ritis ratio was also reported to be a poor prognostic marker.

Figure 3: The Kaplan Meier curve for progression.

This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.

The Kawahara Research Team concluded in their Oncotarget Research Output that first, the study was retrospective in nature.

To reveal the usefulness of the De Ritis ratio as a biomarker, a longer-term study of a larger population with a prospective design should be performed.

Third, this study showed higher age in the higher De Ritis group.

No previous study showed the correlation between AST/ALT value and age.

Thus, further study is needed.

DOI - https://doi.org/10.18632/oncotarget.27944

Full text - https://www.oncotarget.com/article/27944/text/

Correspondence to - Takashi Kawahara - takashi_tk2001@yahoo.co.jp

Keywords - AST, ALT, De Ritis, high risk NMIBC

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105



Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC